Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2007
11/08/2007WO2007126886A1 Process for preparing memantine hydrochloride substantially free of impurities
11/08/2007WO2007126362A1 Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
11/08/2007WO2007126358A1 Diphenylazetidinone derivates possessing cholesterol absor tion inhibitor activit.
11/08/2007WO2007126322A1 A method for obtaining a pharmaceutical composition comprising an active agent ziprasidone or a pharmaceutically acceptable salt thereof
11/08/2007WO2007126264A1 Ginkgo biloba leaf extract having novel composition useful for prevention or treatment of alzheimer's disease and parkinson's disease, and extracting and purifying method thereof
11/08/2007WO2007126111A1 PEPTIDE CAPABLE OF INHIBITING AMYLOID-β FIBROSIS
11/08/2007WO2007126060A1 Salt of 1,2-dihydropyridine compound
11/08/2007WO2007126041A1 Benzisoxazole compound
11/08/2007WO2007126020A1 Compound having activity of blocking nmda receptor channel, and pharmaceutical agent using the same
11/08/2007WO2007125952A1 Amine derivative having npy y5 receptor antagonist activity
11/08/2007WO2007125913A1 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
11/08/2007WO2007125883A1 Composition for improvement in sleep quality
11/08/2007WO2007125720A1 Molecular chaperone expression inducer
11/08/2007WO2007125398A2 : sulfonamide compounds as antagonists of the n-type calcium channel
11/08/2007WO2007125351A1 Pyrimidine derivatives for the treatment of amyloid-related diseases
11/08/2007WO2007125293A1 Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia
11/08/2007WO2007125290A1 Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia
11/08/2007WO2007125287A1 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
11/08/2007WO2007125110A1 N- ( 2-thiazolyl) -amide derivatives as gsk-3 inhibitors
11/08/2007WO2007125109A1 N- (2-thiazolyl) -amide derivatives as gsk-3 inhibitors
11/08/2007WO2007125061A1 Spirocompounds useful as modulators for dopamine d3 receptors
11/08/2007WO2007125049A1 Use of cbx cannabinoid receptor modulators as potassium channel modulators
11/08/2007WO2007124903A1 Spirocyclic cyclohexane derivative with analgesic properties
11/08/2007WO2007124849A2 Inhibitors of the task-1 and task-3 ion channel
11/08/2007WO2007124757A2 Use of escitalopram for improving cognition
11/08/2007WO2007124734A2 Compounds a-r-x for the manufacture of pharmaceutical preparations
11/08/2007WO2007124674A1 Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders
11/08/2007WO2007124618A1 Insulin-like growth factor-enriched nano-products of hairy antler and process for preparation thereof
11/08/2007WO2007104783A3 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators
11/08/2007WO2007104485A3 Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
11/08/2007WO2007099348A3 Cathepsin propeptide and uses thereof
11/08/2007WO2007092854A3 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
11/08/2007WO2007088099A3 Compounds for the treatment of ischemia and neurodegeneration
11/08/2007WO2007082262A3 Novel compounds
11/08/2007WO2007069073A3 Pharmaceutical formulations of amyloid inhibiting compounds
11/08/2007WO2006102933A8 Preparation of autologous haematopoietic stem cells, the methods of production, cyropreservation and use for therapy of traumatic diseases of the central nervous system
11/08/2007WO2006095263A8 Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
11/08/2007US20070259963 N-[5-methanesulfonyl-4-(4-methanesulfonyl-3-pentafluorosulfanylphenoxy)-2-methyl-benzoyl]guanidine; diagnostic agents for hypertension, diabetes, proliferative disorders; inhibitors of the cellular sodium-proton antiporter (Na/H exchanger); good absorption, bioavailability; angina pectoris, infarction
11/08/2007US20070259945 Method for treating pain
11/08/2007US20070259942 Indolone derivatives like N2-[2-(5-Methyl-1H-3-indolyl)ethyl]-N4-(4-methylphenyl)-6-(1-piperidinyl)-2,4-pyrimidinediamine; galanin-type receptors; antidepressants; anxiolytic agents
11/08/2007US20070259922 Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
11/08/2007US20070259920 P2X7, receptor antagonists and uses thereof
11/08/2007US20070259918 2-Hydroxymethyl-3,4,5-Trihydroxy-1-(4-Pentyloxybenzyl) Piperidine as Glucosylceramide Synthase (Gcs) Inhibitor
11/08/2007US20070259912 Polymorphic forms of a GABAA agonist
11/08/2007US20070259908 Mitochondria Activators
11/08/2007US20070259904 Bi-aryl meta-pyrimidine inhibitors of kinases
11/08/2007US20070259898 NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)
11/08/2007US20070259896 N-[3-(3-{[5-(4-Fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}propoxy)phenyl]cyclopropanecarboxamide; PDE10 inhibitor; psychological, nervous system disorders; schizophrenia; cognition activators; drug abuse; antiepileptic agents; lupus; antitumor, -carcinogenic agents; hyperglycemica agents; sarcoidosis
11/08/2007US20070259892 e.g. 1,3-benzothiazol-2-yl (2-chloral -4-pyrimidinyl)acetonitrile; Jun N -terminal kinase inhibitor; anticarcinogenic agent; neuronal disorders, autoimmune diseases, cardiovascular disordres
11/08/2007US20070259887 Inhibitors of polyq-aggregation
11/08/2007US20070259885 Novel Crystal Form of(3-Cyano-1H-Indol-7-Yl)-[4-(4-Fluorophenethyl)Piperazin-1-Yl] Methanone, Hydrochloride
11/08/2007US20070259884 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
11/08/2007US20070259882 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
11/08/2007US20070259873 Selective in presence of at least one other cathepsin isozyme; such as N-{-2-[2-(4-methoxy-phenylamino)-ethylcarbamoyl]-cyclohexyl}-3-methyl-benzamide
11/08/2007US20070259865 Agent for Promoting the Recovery from Dysfunction After the Onset of Central Neurological Disease
11/08/2007US20070259857 Amorphous form of Olanzapine
11/08/2007US20070259853 Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
11/08/2007US20070259835 Phosphinic Acid Derivatives
11/08/2007US20070259827 Compositions and methods for enhancing discriminatory RNA interference
11/08/2007US20070259816 Expression vector comprising nucleotide sequences coding homeobox gene for use in identifying modulators for treatment and prevention of nervous system and seizure disorders
11/08/2007US20070259401 Single-chain polypeptide fusion comprising functional binding, translocation and clostridial neurotoxin heavy chain domain for use as therapeutic agents and/or transporter molecules
11/08/2007US20070258988 Identification and Characterization of Multiple Splice Variants of the Mu Opioid Receptor Gene
11/08/2007US20070258982 Methods of using antibodies against human IL-22
11/08/2007DE60021370C5 Piperazinderivate verwendbar als ccr5 antagonisten Piperazine derivatives useful as antagonists ccr5
11/08/2007DE202006020095U1 Dosierform enthaltend Oxycodon und Naloxon Dosage form comprising oxycodone and naloxone
11/08/2007CA2651002A1 Use of escitalopram for improving cognition
11/08/2007CA2650914A1 Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
11/08/2007CA2650711A1 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
11/08/2007CA2650704A1 Salts of pyridazine compounds
11/08/2007CA2650683A1 Amine derivative having npy y5 receptor antagonist activity
11/08/2007CA2650625A1 Formulations containing pyridazine compounds for treating neuroinflammatory diseases
11/08/2007CA2650577A1 Use of 12-imidazolyl-1-dodecanol or its pharmaceutically acceptable salts for producing a pharmaceutical preparation
11/08/2007CA2650567A1 Use of cbx cannabinoid receptor modulators as potassium channel modulators
11/08/2007CA2650391A1 Inhibitors of the task-1 and task-3 ion channel
11/08/2007CA2650389A1 Pyrimidine derivatives for the treatment of amyloid-related diseases
11/08/2007CA2650326A1 N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
11/08/2007CA2650323A1 N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
11/08/2007CA2649601A1 Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia
11/08/2007CA2649597A1 Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia
11/08/2007CA2649590A1 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
11/08/2007CA2649373A1 Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders
11/08/2007CA2649363A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitor activity
11/08/2007CA2649349A1 Spirocyclic cyclohexane derivatives having an analgesic action
11/08/2007CA2648898A1 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
11/08/2007CA2644819A1 Process for preparing memantine hydrochloride substantially free of impurities
11/07/2007EP1852505A1 Mutations in ion channels
11/07/2007EP1852423A1 Crystal of 4(3h)-quinazolinone derivative
11/07/2007EP1852123A2 Activation and inhibition of the immune system
11/07/2007EP1852113A2 Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
11/07/2007EP1852111A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/07/2007EP1851234A1 Substituted propane phosphinic acid esters
11/07/2007EP1851210A2 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
11/07/2007EP1851209A2 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
11/07/2007EP1851204A1 Naphthalene derivatives as modulators of the glucocorticoid receptor
11/07/2007EP1851197A2 Phenylazetidinone derivatives
11/07/2007EP1850852A2 Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
11/07/2007EP1850848A1 Tetracyclic sulfonamide compounds and methods of use thereof
11/07/2007EP1850840A2 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
11/07/2007EP1850838A2 Inhibition or treatment of dyskinesia
11/07/2007EP1773814B1 Substituted oxindol derivatives and medicaments containing the same
1 ... 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 ... 1833